# Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects with Primary Axillary Hyperhidrosis

> **NCT04159610** · PHASE2 · WITHDRAWN · sponsor: **Dr. August Wolff GmbH & Co. KG Arzneimittel**

## Conditions studied

- Primary Axillary Hyperhidrosis

## Interventions

- **DRUG:** WO3970
- **DRUG:** Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use

## Key facts

- **NCT ID:** NCT04159610
- **Lead sponsor:** Dr. August Wolff GmbH & Co. KG Arzneimittel
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12
- **Primary completion:** 2020-10
- **Final completion:** 2020-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was not pursued for internal reasons
- **Last updated:** 2024-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04159610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04159610, "Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects with Primary Axillary Hyperhidrosis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04159610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*